The biotech sector took in record amounts of venture capital last quarter—the largest amount of venture capital in a single quarter since data provider BioCentury started tracking it in 1994. Partnerships, debt and follow-on offerings were also all up, whereas funding from initial public offerings (IPOs) fell, especially outside the United States. Immuno-oncology continues to feature in major deals, with Celgene acquiring Juno, and Nektar signing a multibillion-dollar licensing deal with Bristol-Myers Squibb.
About this article
Cite this article
DeFrancesco, L. 1Q18—the risk-capital roll continues. Nat Biotechnol 36, 487 (2018). https://doi.org/10.1038/nbt.4160